Bicycle Therapeutics plc – NASDAQ:BCYC

Add to watchlist

$7.16

-7.39

-50.79%

Market closed

Open in about 9 hours

-35.79%

month

-35.79%

quarter

-21.35%

year

Market Cap	994.17M
Enterprise value	341.88M

P/E	-5.47
EV/Sales	23.63
EV/EBITDA	-3.18
Price/Sales	44.02
Price/Book	2.35
PEG ratio	0.12
EPS	-4.45

Revenue	41.59M
EBITDA	-177.73M
Income	-168.14M
Revenue Q/Q	298.66%
Revenue Y/Y	168.39%

Profit margin	-779.35%
Oper. margin	-802.72%
Gross margin	0%
EBIT margin	-802.72%
EBITDA margin	-427.25%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Bicycle Therapeutics Stock Forecast

M Q Y

Last Year

$39.25

Potential upside: 448.18%

Analysts Price target
Financials & Ratios estimates

Bicycle Therapeutics plc (NASDAQ:BCYC): Profit margin
Jun 2023	11.39M	-42.60M	-373.81%
Sep 2023	5.35M	-49.89M	-932.32%
Dec 2023	5.33M	-49.09M	-921.01%
Mar 2024	19.51M	-26.54M	-136.01%

Bicycle Therapeutics plc (NASDAQ:BCYC): Debt to assets
Jun 2023	454170000	234.07M	51.54%
Sep 2023	638683000	222.66M	34.86%
Dec 2023	595344000	224.41M	37.69%
Mar 2024	547143000	191.09M	34.93%

Bicycle Therapeutics plc (NASDAQ:BCYC): Cash Flow
Jun 2023	34.09M	-277K	12.29M
Sep 2023	-1.02M	-502K	234.63M
Dec 2023	-47.28M	-51K	386K
Mar 2024	-70.82M	-11.99K	1.86M

Bicycle Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Bicycle Therapeutics
Employees

Bicycle Therapeutics plc (NASDAQ:BCYC): Employee count
Aug 2023	236
Sep 2023	236
Oct 2023	236
Nov 2023	236
Dec 2023	236
Jan 2024	236
Feb 2024	236
Mar 2024	284
Apr 2024	284
May 2024	284
Jun 2024	284
Jul 2024	284

Bicycle Therapeutics
Hedge Funds Holdings Q3 2022

77.36% +0.70%

of BCYC is owned by hedge funds

72 -6

hedge funds hold BCYC stock

22.93M +241.37K

shares is hold by hedge funds

BCYC hedge funds holdings changes

Bicycle Therapeutics
Insider Trading

Bicycle Therapeutics plc (NASDAQ:BCYC): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	19876
Apr 2024	0	7222
Jul 2024	0	7268
Oct 2024	0	6528
Nov 2024	0	4944
Dec 2024	1485397	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	16 Dec 2024	BAKER BROS. ADVISORS LP director, 10 percent owner: director, 10 percent owner:	American Depositary Shares	457,631	$15.34	$7,020,975
Purchase	16 Dec 2024	BAKER BROS. ADVISORS LP director, 10 percent owner: director, 10 percent owner:	American Depositary Shares	42,369	$15.34	$650,025
Purchase	13 Dec 2024	BAKER BROS. ADVISORS LP director, 10 percent owner: director, 10 percent owner:	American Depositary Shares	566,814	$13.8	$7,824,300
Purchase	13 Dec 2024	BAKER BROS. ADVISORS LP director, 10 percent owner: director, 10 percent owner:	American Depositary Shares	244,587	$13.72	$3,356,712
Purchase	13 Dec 2024	BAKER BROS. ADVISORS LP director, 10 percent owner: director, 10 percent owner:	American Depositary Shares	59,995	$13.63	$817,672
Purchase	13 Dec 2024	BAKER BROS. ADVISORS LP director, 10 percent owner: director, 10 percent owner:	American Depositary Shares	30,241	$13.5	$408,193
Purchase	13 Dec 2024	BAKER BROS. ADVISORS LP director, 10 percent owner: director, 10 percent owner:	American Depositary Shares	52,656	$13.8	$726,863
Purchase	13 Dec 2024	BAKER BROS. ADVISORS LP director, 10 percent owner: director, 10 percent owner:	American Depositary Shares	22,722	$13.72	$311,837
Purchase	13 Dec 2024	BAKER BROS. ADVISORS LP director, 10 percent owner: director, 10 percent owner:	American Depositary Shares	5,573	$13.63	$75,954
Purchase	13 Dec 2024	BAKER BROS. ADVISORS LP director, 10 percent owner: director, 10 percent owner:	American Depositary Shares	2,809	$13.5	$37,916

BCYC insider trading transactions

Bicycle Therapeutics
Executives

Insider	Age	Compensation
Dr. Kevin Lee M.B.A., Ph.D. (1969) Chief Executive Officer & Executive Director	56	$1,160,000
Dr. Michael Skynner Ph.D., B.sc. Ph.d. (1970) Chief Operating Officer	55	$769,010
Mr. Lee H. Kalowski (1981) Pres & Chief Financial Officer	44	$756,130
Dr. Nigel Crockett Ph.D. (1965) Chief Bus. Officer	60	$568,120
Dr. Dominic Smethurst M.A., M.D. (1974) Chief Medical Officer	51	$431,700
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE (1951) Co-Founder, Non-Executive Director & Member of Scientific Advisory Board	74	$40,000

Bicycle Therapeutics
Latest News

Thursday, 12 December 2024
18:30	Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification	businesswire.com
Monday, 2 December 2024
16:05	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Monday, 25 November 2024
17:30	Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update	businesswire.com
Thursday, 7 November 2024
10:04	Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern	seekingalpha.com
Friday, 1 November 2024
16:05	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Thursday, 31 October 2024
07:00	Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results	businesswire.com
Wednesday, 23 October 2024
07:00	Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals	businesswire.com
Wednesday, 16 October 2024
07:00	Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress	businesswire.com
Monday, 14 October 2024
06:40	Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?	zacks.com
Saturday, 14 September 2024
03:00	Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024	businesswire.com
Friday, 6 September 2024
13:37	Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone	benzinga.com
Tuesday, 20 August 2024
07:37	Bicycle Therapeutics Is Looking Increasingly Attractive	seekingalpha.com
Friday, 9 August 2024
13:01	What Makes Bicycle Therapeutics (BCYC) a New Buy Stock	zacks.com
10:55	Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?	zacks.com
Thursday, 1 August 2024
16:05	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Monday, 22 July 2024
07:00	Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024	businesswire.com
Thursday, 27 June 2024
10:40	Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?	zacks.com
Friday, 21 June 2024
09:25	Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio	zacks.com
Tuesday, 11 June 2024
10:40	Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?	zacks.com
Monday, 3 June 2024
07:00	Bicycle Therapeutics to Participate in Upcoming Investor Conferences	businesswire.com
Friday, 24 May 2024
13:25	Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M	zacks.com
10:56	Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet	zacks.com
Thursday, 23 May 2024
17:05	Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting	businesswire.com
07:00	Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing	businesswire.com
Tuesday, 21 May 2024
10:46	Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?	zacks.com
Monday, 6 May 2024
13:01	Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade	Zacks Investment Research
10:56	Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?	Zacks Investment Research
Monday, 25 March 2024
13:07	2 More Potential Biotech Buyout Targets	Seeking Alpha
Tuesday, 5 March 2024
16:35	Bicycle Therapeutics to Present at the AACR Annual Meeting 2024	Business Wire
Tuesday, 12 September 2023
09:05	Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up	Zacks Investment Research

Frequently Asked Questions (FAQ)

What's the price of Bicycle Therapeutics stock today?

One share of Bicycle Therapeutics stock can currently be purchased for approximately $7.16.
When is Bicycle Therapeutics's next earnings date?

Unfortunately, Bicycle Therapeutics's (BCYC) next earnings date is currently unknown.
Does Bicycle Therapeutics pay dividends?

No, Bicycle Therapeutics does not pay dividends.
How much money does Bicycle Therapeutics make?

Bicycle Therapeutics has a market capitalization of 994.17M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 86.52% to 26.98M US dollars.
What is Bicycle Therapeutics's stock symbol?

Bicycle Therapeutics plc is traded on the NASDAQ under the ticker symbol "BCYC".
What is Bicycle Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Bicycle Therapeutics?

Shares of Bicycle Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Bicycle Therapeutics's key executives?
Bicycle Therapeutics's management team includes the following people:
- Dr. Kevin Lee M.B.A., Ph.D. Chief Executive Officer & Executive Director(age: 56, pay: $1,160,000)
- Dr. Michael Skynner Ph.D., B.sc. Ph.d. Chief Operating Officer(age: 55, pay: $769,010)
- Mr. Lee H. Kalowski Pres & Chief Financial Officer(age: 44, pay: $756,130)
- Dr. Nigel Crockett Ph.D. Chief Bus. Officer(age: 60, pay: $568,120)
- Dr. Dominic Smethurst M.A., M.D. Chief Medical Officer(age: 51, pay: $431,700)
- Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE Co-Founder, Non-Executive Director & Member of Scientific Advisory Board(age: 74, pay: $40,000)
Is Bicycle Therapeutics founder-led company?

Yes, Bicycle Therapeutics is a company led by its founder Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE.
How many employees does Bicycle Therapeutics have?

As Jul 2024, Bicycle Therapeutics employs 284 workers.
When Bicycle Therapeutics went public?

Bicycle Therapeutics plc is publicly traded company for more then 6 years since IPO on 23 May 2019.
What is Bicycle Therapeutics's official website?

The official website for Bicycle Therapeutics is bicycletherapeutics.com.
How can i contact Bicycle Therapeutics?

Bicycle Therapeutics can be reached via phone at +44 1223 261503.
What is Bicycle Therapeutics stock forecast & price target?

Based on 4 Wall Street analysts` predicted price targets for Bicycle Therapeutics in the last 12 months, the avarage price target is $39.25. The average price target represents a 448.18% change from the last price of $7.16.

Bicycle Therapeutics plc

bicycletherapeutics.com

Exchange:

NASDAQ

Full time employees:

284

Industry:

Biotechnology

Sector:

Healthcare

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

+44 1223 261503

Babraham Research Campus
Cambridge, CB22 3AT

CIK: 0001761612
ISIN: US0887861088
CUSIP: 088786108